What We’re Reading: Biden May Cut MA Funding; Historic Drug Shortages; Health System Changes Anticipated at PHE EndMarch 23rd 2023
The Biden administration might implement changes on how it would fund private Medicare Advantage (MA) plans; by the end of 2022, drug shortages increased by almost 30%; the end of the COVID-19 public health emergency (PHE) is expected to bring major changes to the US health system.
Experts Call for a More Patient-Focused Approach to Prior AuthorizationMarch 23rd 2023
On the first full day of conference activity at AMCP 2023, a morning session examined prior authorization (PA) through a lens of refining the current process and the potential role of clinical trial data in PA criteria.
Study Finds Vaccine Effectiveness Lowers as Time Increases From Last DoseMarch 22nd 2023
Protection against COVID-19 and vaccine effectiveness increased after receiving 1 or 2 booster doses compared with a primary series alone, but vaccine effectiveness generally declined as the time since last dose increased.
What We’re Reading: Organ Transplant System Overhaul; More COVID-19 Boosters; Hormonal Birth Control and CancerMarch 22nd 2023
The US organ transplant system might face an overhaul in a proposal to be announced on Wednesday after years of criticism; the FDA may decide whether to approve additional COVID-19 booster vaccinations for vulnerable populations; a new study finds the same, small breast cancer risk in multiple forms of hormonal birth control.
Pediatric Patients See Benefit in Short-, Long-term Treatment for ADMarch 22nd 2023
Data from the LIBERTY AD PRESCHOOL trial, and its ongoing open-label extension analysis show that dupilumab is safe and clinically effective, and can lead to statistically significant symptom improvement among patients aged 6 months to 17 years who have moderate to severe atopic dermatitis (AD).
Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL
A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
What We’re Reading: Minnesota’s Abortion Refuge Status; Moderna’s $130 COVID-19 Vaccine; Biogen’s ALS Drug Awaits FDA ApprovalMarch 21st 2023
Minnesota looks to create abortion refuge for patients and providers; Moderna’s expected price single dose of COVID-19 sits at $130; FDA staff sees a "clinical benefit" in Biogen’s ALS drug.
Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel SaysMarch 21st 2023
A panel assembled at the American Academy of Dermatology 2023 Annual Meeting encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
COA to Celebrate 20 Years of Advocacy at Annual Conference
Topics to be addressed at the annual conference, which will bring more than 1900 attendees to Kissimmee, Florida, include the Enhancing Oncology Model, efforts to regulate pharmacy benefit managers, and 340B reform.
Patient Outcomes Improve on Several Fronts Following Treatment for Prurigo NodularisMarch 20th 2023
Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.
Dangerous Drug-Resistant Yeast Infection Rising Across the US, CDC SaysMarch 20th 2023
Candida auris was first reported in the United States in 2016; the highly contagious fungal infection has been labeled an “urgent threat” by the CDC, and its spread may have aided by underresourced public health systems.
What We’re Reading: Wyoming Abortion Pill Ban; Reducing Racial Disparities in Health Care; Affordable Insulin in CaliforniaMarch 20th 2023
Gov. Mark Gordon sings a ban on the use of abortion pills in Wyoming; a new study shows that Affordable Care Act has reduced racial disparities in health care; California Gov. Gavin Newsom announces a contract to make affordable insulin.